文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

免疫介导炎症性疾病患者SARS-CoV-2检测与感染风险的人群分析

Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-09-27

基于加拿大安大略省2020年成年居民的人群匹配队列研究,纳入493499例免疫介导炎症性疾病(IMID)患者与2466946例非IMID对照。IMID患者至少接受一次SARS-CoV-2检测的比例更高(27.4% vs 22.7%),但两组检测阳性比例相同(均为0.9%);IMID患者检测 odds 高20%(OR 1.20,95%CI 1.19-1.21),感染 odds 在各IMID亚组间存在差异,多数亚组未显著升高。

要点

  • IMID患者SARS-CoV-2检测率高于对照(27.4% vs 22.7%),阳性率相同(0.9%)。
  • IMID患者检测 odds 升高20%(OR 1.20,95%CI 1.19-1.21)。
  • 感染 odds 因IMID亚组而异,IBD和MS较低,RA和虹膜炎 marginally 较高。

核心结论

  • 所有IMID患者较非IMID对照更可能接受SARS-CoV-2检测,但感染风险因疾病亚组而异。

主要发现

  • IMID患者至少一次SARS-CoV-2检测比例为27.4%,非IMID对照为22.7%。
  • 两组SARS-CoV-2检测阳性比例均为0.9%。
  • IMID患者检测 odds 升高20%(OR 1.20,95%CI 1.19-1.21)。
  • 多数IMID亚组感染 odds 未较非IMID对照显著升高,IBD和MS感染 odds 较低,RA和虹膜炎 marginally 较高。

关键数值与推荐

  • IMID患者检测 odds 比非IMID对照高20%(OR 1.20,95%CI 1.19-1.21)。
  • IMID患者与非IMID对照的SARS-CoV-2检测阳性比例均为0.9%。

临床怎么用

  • 对于IMID患者,应认识到其SARS-CoV-2检测率较高但阳性率与普通人群相当,感染风险需结合具体疾病亚组评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the incidence of and factors associated with SARS-CoV-2 testing and infection in immune-mediated inflammatory disease (IMID) patients versus matched non-IMID comparators from the general population. METHODS: We conducted a population-based, matched cohort study among adult residents from Ontario, Canada, from January 2020 to December 2020. We created cohorts for the following IMIDs: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases, multiple sclerosis (MS), iritis, inflammatory bowel disease (IBD), polymyalgia rheumatica, and vasculitis. Each patient was matched with 5 patients without IMIDs based on sociodemographic factors. We estimated the incidence of SARS-CoV-2 testing and infection in IMID patients and non-IMID patients. Multivariable logistic regressions assessed odds of SARS-CoV-2 infection. RESULTS: We studied 493,499 patients with IMIDs and 2,466,946 patients without IMIDs. Patients with IMIDs were more likely to have at least 1 SARS-CoV-2 test versus patients without IMIDs (27.4% versus 22.7%), but the proportion testing positive for SARS-CoV-2 was identical (0.9% in both groups). Overall, IMID patients had 20% higher odds of being tested for SARS-CoV-2 (odds ratio 1.20 [95% confidence interval 1.19-1.21]). The odds of SARS-CoV-2 infection varied across IMID groups but was not significantly elevated for most IMID groups compared with non-IMID comparators. The odds of SARS-CoV-2 infection was lower in IBD and MS and marginally higher in RA and iritis. CONCLUSION: Patients across all IMIDs were more likely to be tested for SARS-CoV-2 versus those without IMIDs. The risk of SARS-CoV-2 infection varied across disease subgroups.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Eder L, Croxford R, Drucker AM, et al. Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing. Arthritis Care Res (Hoboken). 2022. PMID: 34486829. doi:10.1002/acr.24781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。